Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma

(2013) Jonathan L. Kaufman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers

(2013) S. V. Govindan et al.   MOLECULAR CANCER THERAPEUTICS

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

(2012) P. Gupta et al.   BLOOD

Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies

(2012) Y. Mao et al.   CLINICAL CANCER RESEARCH

CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease

(2011) Federica Borghese et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival

(2011) Idit Shachar et al.   LEUKEMIA & LYMPHOMA

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Milatuzumab: a promising new agent for the treatment of lymphoid malignancies

(2008) Tomer Mark et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS